Some good news from the Ohio Statehouse.
1. H.B. 485, the Baby Olivia Act, was passed last week in the Ohio House of Representatives 59-27 along party lines. The act requires all Ohio public schools to teach health and human development in grades 5-12. Teaching is to include showing a high-definition ultrasound video of early fetal development which depicts each stage of development from fertilization to birth such as the video Meet Baby Olivia. The bill has been introduced in the Ohio Senate. Democrats and their allies in the abortion industry are opposed to anything that humanizes an individual in the womb as anything beyond a clump of human cells.
A Never Before Seen Look At Human Life In The Womb | Baby Olivia
House Bill 485 – Enact the Baby Olivia Act
Sex-ed group likens ‘Baby Olivia’ video to horror film ‘Rosemary’s Baby’
2. H.B. 324, the Patient Protection Act, was also passed last week in the Ohio House of Representatives 60-28 along party lines. This bill has also been introduced in the Ohio Senate. The bill requires in-person exams, clear disclosure of risks, and follow up care for drugs that cause serious adverse effects in over 5% of patients. The prompter for this act was a study released earlier this year by the Ethics and Public Policy Center (EPPC). The study looked at mifepristone which is a drug the FDA approved for chemical abortions in 2000. FDA approval cited a severe side effect risk of 0.5%. Initially, prescribing of mifepristone required (REMS – risk evaluation and mitigation strategy) three in-person office visits inclusive of a follow-up visit, maximum gestational age of 7 weeks, drug prescribed only by a physician, drug dispensed in office, drug taken in office, and mandatory reporting of adverse events. In 2023, the REMS for mifepristone were reduced requiring no in-person visits, prescriptions written by providers other than physicians permitted, use up to 10 weeks gestation, and NO required reporting of adverse events. The EPPC study performed a data analysis from an all-payer insurance claims database that included 865,727 mifepristone abortions from 2017-2023. A key finding from the analysis revealed that 10.93% of women experienced sepsis, infection, hemorrhaging, or another serious or life threatening adverse event within 45 days following a mifepristone abortion. I find it ironic that a group of individuals who have proclaimed from the mountain tops that abortion is health care and that abortion must be legalized because of the scourge of “back alley” abortions are A-OK with handing out mifepristone like candy from a Pez dispenser. First off, mifepristone has a 10 week window of opportunity. Let’s have an initial office visit to date the pregnancy. Second, retained products of conception (parts of the placenta remaining attached to the uterine wall) are a very serious abortion complication. A post abortion office visit is essential in determining the success of a chemical abortion. Third, H.B. 324 covers ALL FDA approved medications that have a substantial risk of severe side effects. Mifepristone is only one of a growing list of medications that are NAS-TAY regarding side effect profile. I find it sad that politicians have to spank the medical establishment into line – many of the individuals who testified in opposition to this legislation were ACOG (American College of Obstetricians and Gynecologists) members.
House Bill 324 – Enact the Patient Protection Act
doctordeplorablemf
